Allergy Therapeutics Share Price (AGY)

31.00 0.00 (0.00%) delayed: 11:34AM BST
Bid price 30.50 Open price 31.00
Ask price 31.50 Prev close 31.00
High price 31.25 Spread 3.17%
Low price 30.75 Volume 43,803

Register now for FREE live Allergy Therapeutics share prices, Allergy Therapeutics stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Allergy Therapeutics Level 2 Data, indepth research tools and investor commentary for Allergy Therapeutics (AGY) and other London Stock Exchange equities.

Allergy Therapeutics Share Price Chart

Advanced Charts >>

Register now for FREE Allergy Therapeutics share price charts

Allergy Therapeutics Share Price Information

Name Allergy Therapeutics Epic AGY
Sector Pharmaceuticals & Biotechnology ISIN GB00B02LCQ05
Activites Allergy Therapeutics plc is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving revenue in the last financial year of £42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging markets. Index n/a

Allergy Therapeutics Key Numbers

Latest Share Price (p) 31.00 Net Gearing (%) 5.20
Market Capitalisation (£m) 184.18 Gross Gearing (%) 46.50
Shares in issue (m) 594.12 Debt Ratio 31.33
P/E Ratio -13.54 Debt-to-Equity Ratio 0.53
Total dividends per share (p) 0.00 Assets / Equity Ratio 1.87
Dividend Yield (%) 0.00 Price to book value 6.07
Dividend cover (x) 0.00 ROCE (%) -27.31
Earning per share (p) -2.29 EPS Growth (%) -11,550.00
52 week high / low 32.13 / 16.38 DPS Growth (%) n/a

Allergy Therapeutics Director Deals

Dec.Date Type Director Pos No. of Shares
29/09/2016 BUY Peter Jensen CH 30,000
28/09/2016 BUY Nick Wykeman FD 150,000
26/09/2016 BUY Manuel Llobet CEO 100,000
27/07/2015 BUY Manuel Llobet CEO 50,000
10/12/2012 EXR Ian Postlethwaite RES 1,500,000

More Allergy Therapeutics Director Deals >>

Allergy Therapeutics Company News

07:00 18/07/2017

Trading Update

RNS Number : 3133L Allergy Therapeutics PLC 18 July 2017         Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group")   Trading Update   15% constant currency revenue growth Double-digit compound annual revenue growth over the past...

09:40 18/07/2017

Broker Forecast - finnCap issues a broker note on Allergy Therapeutics PLC

finnCap today reaffirms its buy investment rating on Allergy Therapeutics PLC (LON:AGY) and raised its price target to 46p (from 43p). Story provided by

08:04 18/07/2017

Allergy Therapeutics ahead of forecasts

Allergy Therapeutics expects revenues for the year ended 30 June to be ahead of market forecasts at £64.1m (2016: £48.5m). A year-end update said the strong performance represented 15% annual growth on a constant currency basis and 32% on a reported basis which reflected the favourable euro...

More Allergy Therapeutics Company News >>

Register now for FREE Allergy Therapeutics company news

Allergy Therapeutics Share Price Discussions

6 days ago

Allergy Therapeutics PLC (AGY)

Mission Statement To create a sustainable, fast-growing and profitable global speciality pharmaceutical business with a substantial franchise in the allergy sector by developing innovative, patented, registered therapies for both the treatment and prevention of allergy-related conditions....

more than 1 year ago

Allergy TV Clip re: Successful Phase II Study (AGY)

more than 1 year ago

Allergy Therapeutics (AGY)

Good morning, Below is a short TV interview with Manuel & Ian covering today's interim results.

Register now for FREE Allergy Therapeutics share price discussions